Medicus Pharma Ltd. (MDCX)

NCM – Цена в реальном времени. Валюта: USD

0.32

-0.02 (-5.26%)

При закрытии: May 12, 2026, 4:00 PM EDT

0.31

-0.00 (-1.56%)

До открытия: May 13, 2026, 8:55 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Medicus Pharma Ltd. (MDCX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Medicus Pharma Ltd. (MDCX)

Medicus Pharma highlights positive dose-response in updated skin cancer trial results

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma advances Skinject in rare disease – ICYMI

Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Видео

No Data

Пресс-релизы

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Search stocks

Medicus Pharma Ltd. (MDCX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Medicus Pharma Ltd. (MDCX)

Medicus Pharma highlights positive dose-response in updated skin cancer trial results

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma advances Skinject in rare disease – ICYMI

Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Видео

No Data

Пресс-релизы

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention